William Vickery joins Hybrigenics as Head of Corporate and Business Development
Hybrigenics announced it has hired William Vickery as Head of Corporate and Business Development, a newly created position.
William worked for five years at ExonHit Therapeutics as Senior Director of Business Development. During this time, he negotiated multiple extensions to ExonHit Therapeutics’ strategic partnership with Allergan, secured it’s participation in PharmaCog (the European Innovative Medicines Initiative consortium on Alzheimer’s disease) and in-licensed a breast cancer diagnostic discovered by Gustave Roussy Institute.
Prior to joining ExonHit Therapeutics in 2006 and since 2003, William served as a Business Development Director of Roche Pharmaceuticals in the US. During his tenure, he was responsible for out-licensing and divestiture of Roche-developed assets. He led the Roche strategic alliance teams which established the alliances with Syrrx and Amira. From 2000 to 2003, he held various positions at Roche Pharmaceuticals headquarters in Switzerland, including business development responsibilities for CNS and metabolic diseases. He received an MBA from INSEAD and an engineering degree from HEI (Lille, France).
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Atomic-scale view of bacterial proteins offers path to new tuberculosis drugs
Dynamix Pharmaceuticals Completes a $10M Series A Financing - Signs a Collaboration Deal with Teva Pharmaceutical Industries
glyconet Berlin Brandenburg e.V. - Potsdam, Germany
Medicom,_the_African_Journal_of_Hospital_Medicine
Highlights of June 2017 EMA Management Board meeting - Focus on Brexit preparations and the development of the EU clinical trial portal and database
Promising new therapy to target MAGE-A1 positive solid tumors - T-knife Therapeutics announces dosing of first patient with TK-8001 in the IMAG1NE phase 1/2 clinical trial
Bitop AG Reports That Ectoin Reduces Symptoms of Acute Allergic Rhinitis
